268 related articles for article (PubMed ID: 23867025)
1. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
[TBL] [Abstract][Full Text] [Related]
2. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
[TBL] [Abstract][Full Text] [Related]
3. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.
Scosyrev E; Wu G; Golijanin D; Messing E
BJU Int; 2012 Nov; 110(10):1485-90. PubMed ID: 22448649
[TBL] [Abstract][Full Text] [Related]
6. Psychological research and the prostate-cancer screening controversy.
Arkes HR; Gaissmaier W
Psychol Sci; 2012 Jun; 23(6):547-53. PubMed ID: 22555966
[TBL] [Abstract][Full Text] [Related]
7. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
[TBL] [Abstract][Full Text] [Related]
8. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
O'Dell KJ; Volk RJ; Cass AR; Spann SJ
J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
[TBL] [Abstract][Full Text] [Related]
10. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
12. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
[TBL] [Abstract][Full Text] [Related]
13. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
Schröder FH
N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
[No Abstract] [Full Text] [Related]
14. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
15. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
Caire AA; Sun L; Robertson CN; Polascik TJ; Maloney KE; George DJ; Price MM; Stackhouse DA; Lack BD; Albala DM; Moul JW
Urology; 2010 May; 75(5):1122-7. PubMed ID: 19815259
[TBL] [Abstract][Full Text] [Related]
16. The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men.
Hevey D; Pertl M; Thomas K; Maher L; Chuinneagáin SN; Craig A
Patient Educ Couns; 2009 Feb; 74(2):244-9. PubMed ID: 18848753
[TBL] [Abstract][Full Text] [Related]
17. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.
Messing EM; Albertsen P; Andriole GL; Carroll PR; Klein EA
Urol Oncol; 2012; 30(1):117-9. PubMed ID: 22243597
[No Abstract] [Full Text] [Related]
18. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
Brett AS; Ablin RJ
N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
[No Abstract] [Full Text] [Related]
19. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
Kwiatkowski M; Klotz L; Hugosson J; Recker F
Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762
[No Abstract] [Full Text] [Related]
20. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
